Department Courses

Online registration is CLOSED.

Neuroendocrine tumors (NETs) pose numerous clinical challenges due to their rarity, heterogeneity and lack of standardized diagnostic and therapeutic strategies. Over the last five years, the treatment landscape and biologic understanding of neuroendocrine tumors has shifted dramatically with significant advancements in diagnosis, loco-regional and systemic therapies rapidly being developed. Several large randomized phase III trials of novel treatments have resulted in new drug approvals and the increased knowledge of specific pathways implicated in neuroendocrine tumor growth has shifted the focus of many clinical trials.

In light of these exciting new developments, this conference has been customized to provide the latest evidence based practice to health care professionals. Each session will address how the expanding treatment choices and research studies will influence individual treatment plans and impact NET patient management in the future. Don’t miss out on this important and informative symposium.

Courtyard Bellevue Downtown
11010 NE 8th Street
Bellevue, WA
Upon completion of the activity, participants should be able to:
  1. Recognize various NET disease presentations.
  2. Interpret current advances in the histopathology of both primary and metastatic NETs and how classification determines diagnostic approach, management and prognosis.
  3. Compare the strengths and weaknesses of different imaging modalities to accurately identify the primary tumor and measure treatment response.
  4. Identify new diagnostic and therapeutic agents that are impacting the practice of functional and molecular imaging.
  5. Describe the surgical interventions available for different NET sites and explain the importance of an experienced NET surgeon evaluation for patients with multi-faceted, complex disease processes.
  6. Illustrate the safety and efficacy of surgical and regional approaches in the management of hepatic metastases.
  7. Define the significance of patient selection and the impact of tumor burden and location in determining which methodologies for liver tumors is appropriate.
  8. Differentiate the new therapeutic options for syndrome control and how to determine the initiation and sequence of treatment.
  9. Evaluate the etiology of hormone related fibrosis and carcinoid heart disease when forming diagnostic and management strategies to minimize the clinical complications from these two conditions.
  10. Distinguish how NET biology of G3 tumors, grading parameters and clinical behavior can change diagnostic and treatment decisions.
  11. Formulate a treatment plan by comparing the clinical effectiveness for the various targeted and therapeutic options available for patients with metastatic disease.
  12. Summarize how the biology of pulmonary NETs can change diagnostic, surgical and medical approaches.
  13. Establish the role and position of surgical and targeted therapeutic options to create an appropriate treatment plan for patients with lung NETs.
  14. Critique the clinical trial results and research data of Peptide Receptor Radionuclide Therapy (PRRT) to determine the optimal timing and sequence of this treatment option.
  15. Explain the future directions in theranostics from a research and clinical perspective.
  16. Illustrate the value of creating a multidisciplinary team and communication system to improve the quality of care for NET patients.


Attendees are responsible for all airfare, lodging, and transportation costs.  The program fee includes:  Catered breakfast and lunch and breaks, and all instructional materials.  

To enroll, click on the blue "Register" button. Allow up to fifteen working days to receive your email confirmation of enrollment. If you have not received confirmation prior to your departure for the course, please contact the CME office at 206.543.1050. Continuing Medical Education will not be responsible for expenses incurred by an individual who is not confirmed.



Allied Health


 *Resident/Fellow /Students            


*proof of current residency, fellowship, or enrollment required.

Cancellation Policy:  The Office of Continuing Medical Education must receive written notification of your cancellation by February 15, 2018. A $30.00 processing fee will be deducted from refund requests received by this date. No refunds will be issued following February 15, 2018. The Office of Continuing Medical Education reserves the right to cancel this course twenty (20) days prior to the course date when a minimum enrollment is not met or for other reasons that prevent the University from holding the course. Each registrant will be notified by telephone followed by written notification and a full refund. The University of Washington is not responsible for any other costs incurred such as non-refundable airline tickets or hotel penalties. Contact the CME Office with questions: call 206.543.1050, fax 206.221.4525 or email cme@uw.edu.

Stacey Cohen, MD
Assistant Professor of Medicine, Division of Medical Oncology
University of Washington
Seattle, WA
Felicia Cummings, MD
Department of Radiology
Virginia Mason Medical Center
Seattle, WA
Farhood Farjah, MD, MPH
Associate Professor of Surgery, Division of Cardiothoracic Surgery
University of Washington
Seattle, WA
Renuka Iyer, MD
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Guy Johnson, MD, PharmD
Assistant Professor, Department of Radiology, Division of Interventional Radiology
University of Washington
Seattle, WA
Hagen Kennecke, MD
Medical Oncologist
Virginia Mason Medical Center
Seattle, WA
Janet Leung, MD
Department of Endocrinology, Division of Endocrinology, Metabolism & Diabetes
Virginia Mason Medical Center
Seattle, WA
Erik Mittra, MD
Department of Nuclear Medicine, Division of Diagnostic Radiology
Oregon Health & Science University
Portland, OR
Venu Pillarisetty, MD
Associate Professor, Department of Surgical Oncology, Division of General Surgery
University of Washington
Seattle, WA
Flavio Rocha, MD
Department of Surgery
Virginia Mason Medical Center
Seattle, WA
Kit Wong, MD
Assistant Professor of Medicine, Division of Medical Oncology
University of Washington
Seattle, WA
Title Time Faculty Room
& Breakfast 7:30AM - 8:00AM  
Welcome & Opening Remarks 8:00AM - 8:05AM Kit Wong, MD
Hagen Kennecke, MD
General Overview 8:05AM - 8:20AM Kit Wong, MD
Session 1: Diagnostic Approaches & Surveillance 8:05AM - 9:25AM  
Principles of Pathology for Diagnosis of Pancreatic and Intestinal NETs 8:20AM - 8:35AM Renuka Iyer, MD
Imaging Modalities and Applications 8:35AM - 8:50AM Felicia Cummings, MD
Molecular Imaging 8:50AM - 9:10AM Erik Mittra, MD
Question & Answer Session 9:10AM - 9:25AM Kit Wong, MD
Felicia Cummings, MD
Erik Mittra, MD
Renuka Iyer, MD
Session 2: Surgical Challenges & Controversial Issues for Management of NETs 9:25AM - 10:45AM  
Surgical Assessment 9:25AM - 9:35AM Venu Pillarisetty, MD
Open vs. Laparoscopic Resections - Which Is the Optimal Strategy? 9:35AM - 9:50AM Venu Pillarisetty, MD
Evolving Role of the NET Surgeon 9:50AM - 10:00AM Venu Pillarisetty, MD
Hepatic Surgery for Metastatic NETs 10:00AM - 10:15AM Flavio Rocha, MD
Surgical Exploration 10:15AM - 10:30AM Flavio Rocha, MD
Question & Answer Session 10:30AM - 10:45AM Venu Pillarisetty, MD
Flavio Rocha, MD
Break 10:45AM - 11:00AM  
Interventional Radiology 11:00AM - 11:20AM Guy Johnson, MD, PharmD
Session 3: Interventional Radiology Approaches for Liver-Dominant Disease 11:00AM - 11:30AM  
Question & Answer Session 11:20AM - 11:30AM Guy Johnson, MD, PharmD
Carcinoid Syndrome Symptom Control 11:30AM - 11:45AM Kit Wong, MD
Session 4: Therapies for Symptom Control 11:30AM - 12:15PM  
Other Syndromes and Symptoms Associated with NETs 11:45AM - 12:05PM Janet Leung, MD
Question & Answer Session 12:05PM - 12:15PM Kit Wong, MD
Janet Leung, MD
GI NETs 12:15PM - 12:25PM Hagen Kennecke, MD
Session 5: Medical Management for Progressive Disease 12:15PM - 12:55PM  
Pancreatic NETs 12:25PM - 12:35PM Hagen Kennecke, MD
Poorly Differentiated NETs 12:35PM - 12:40PM Hagen Kennecke, MD
Current Clinical Trials 12:40PM - 12:45PM Hagen Kennecke, MD
Question & Answer Session 12:45PM - 12:55PM Hagen Kennecke, MD
Lunch (included) 12:55PM - 1:30PM  
Peptide Receptor Radionucleide Therapy (PRRT) 1:30PM - 1:35PM Erik Mittra, MD
Session 6: Radiolabeled Peptides - A New Era in Treatment of NETs 1:30PM - 2:25PM  
Background & European Clinical Experience 1:35PM - 1:40PM Erik Mittra, MD
Selection Criteria 1:40PM - 1:45PM Erik Mittra, MD
NETTER 1 Trial: Study Objectives & Design 1:45PM - 1:50PM Erik Mittra, MD
Preventing Toxicities & Nausea 1:50PM - 1:55PM Erik Mittra, MD
Where Should PRRT Be in the Treatment Paradigm? 1:55PM - 2:00PM Erik Mittra, MD
Get Prepared 2:00PM - 2:05PM Erik Mittra, MD
Future Directions & Current Clinical Trials 2:05PM - 2:10PM Erik Mittra, MD
SB Case 2:10PM - 2:25PM Hagen Kennecke, MD
Overview & Diagnosis 2:25PM - 2:40PM Renuka Iyer, MD
Session 7: Pulmonary NETs: Challenges in Diagnosis & Management 2:25PM - 3:50PM  
Surgical Resection 2:40PM - 2:55PM Farhood Farjah, MD, MPH
Medical Therapy 2:55PM - 3:10PM Renuka Iyer, MD
Follow-Up 3:10PM - 3:20PM  
Future Considerations & Current Clinical Trials 3:20PM - 3:35PM  
Lung NET Case 3:35PM - 3:50PM Stacey Cohen, MD
Closing Remarks & Adjourn 3:50PM - 3:55PM Kit Wong, MD
Hagen Kennecke, MD

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Nurses  will be given a certificate of attendance which will fulfill licensure/relincensure  requirements in Washington State.

The symposium is being held at the

Courtyard Bellevue Downtown Hotel

*11010 NE 8th Street*

Bellevue, Washington, 98004

For reservations phone: (425) 454-5888

Target Audience: This forum is designed for physicians and other health professionals from a variety of settings and levels to include the specialties of oncology, endocrinology, surgery, pathology, internal medicine, nursing, gastroenterology, nuclear medicine, diagnostic radiology, intervention radiology, and primary care. Leading experts in the field will discuss, through lectures and panel discussions, the different aspects of diagnosis, histopathology, surgery, hepatic-directed therapy and various systemic treatments targeted to specific NET origins. There will be several opportunities for audience questions and networking with faculty.

Faculty Disclosure:  All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. 

To request disability accommodation, contact the Disability Services Office at 206-543-6450 (voice), 206-543-6452 (TTY), 206-685-7264 (fax), or dso@uw.edu. The University of Washington makes every effort to honor disability accommodation requests. Requests can be responded to most effectively if received as far in advance of the event as possible, preferably at least 10 days.

Follow UW CME on Facebook and Twitter.

Would you like to support UW CME? Click here to donate now.

Privacy | Contact Us | Terms | UW Medicine